
Articles
-
2 days ago |
pharmaphorum.com | Nicole Raleigh
Axtria Inc., an AI-first data analytics innovator and global provider of cloud software to the life sciences industry, today announced the launch of Axtria InsightsMAx.ai. The next generation agentic platform reimagines how life sciences organisations harness AI through a flexible enterprise-grade infrastructure that accelerates experimentation, deployment, and ROI.
-
2 days ago |
pharmaphorum.com | Nicole Raleigh
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated.
-
1 week ago |
pharmaphorum.com | Nicole Raleigh
Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory compliance.
-
1 week ago |
pharmaphorum.com | Nicole Raleigh
In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possibilities from the panel discussion.
-
3 weeks ago |
pharmaphorum.com | Nicole Raleigh
This article was organised, funded, and reviewed by Sanofi. 'Diabetes' as a general term is a condition the public are well-versed in. But, while GLP-1s make the headlines with the possibilities they offer as regards Type 2 diabetes (T2D), it is with a different lens that Type 1 diabetes (T1D) must be viewed, and with a different mindset that symptoms must be treated and managed. Fundamentally, T1D is an autoimmune disease with no cure, and which cannot be prevented.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →